Allos Therapeutics to provide FOLOTYN data for blood cancers at ASH Annual Meeting Allos Therapeutics, Inc. ‘Allos is focused on exploring the potential of FOLOTYN to handle the procedure needs for patients with devastating illnesses, such as for example T-cell lymphoma. We are pleased that the American Society of Hematology has selected these important findings to be included in this year’s meeting and look forwards to sharing the full outcomes with the hematology community in December.’ FOLOTYN, a folate analogue metabolic inhibitor, may be the first and only drug authorized in the U.S.‘.
Adolescent fatness may risk future end-stage renal disease By Sally Robertson, medwireNews Reporter Being overweight or obese in adolescence increases someone’s risk for end-stage renal disease in afterwards lifestyle, report researchers. Their research demonstrated that high body mass index in adolescence is associated with the advancement of both diabetic and non-diabetic ESRD. In a retrospective evaluation of 1 1,194,704 Israeli adolescents, aged a mean of 17.4 years, who underwent health examinations for military service between 1967 and 1997, the team linked health data to the Israeli ESRD registry, which holds information on any sufferers receiving treatment for ESRD between 1980 and 2010.